Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals and medicinal chemicals in India. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease; Rifamycin-O for the treatment of traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy; and Lovastatin. The company was incorporated in 1981 and is based in Mumbai, India.
| Current Price | ₹395.10 |
|---|---|
| Market Cap | ₹4,305 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 92.3 |
| Return on Equity | 17.41% |
| 52-Week Range | ₹225.05 – ₹479.00 |
| Beta (1Y) | 1.05 |
| Dividend Yield | 0.17% |
1. Manufacturing Bulk Drugs-100%
Gujarat Themis Biosyn Ltd. is trading at ₹395.10, with a market capitalisation of ₹4,305 Cr.
Gujarat Themis Biosyn Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Medicinal Chemicals and Botanical Products).
Gujarat Themis Biosyn Ltd. has a P/E of 92.3 and a return on equity of 17.41%.